Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients.
Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C, Copetti M, Castellana S, Valori VM, Morritti M, Graziano P, Luigi C, Coco M, Picardo F, Mazza T, Evron E, Murgo R, Maiello E, Esteller M, Fazio VM, Parrella P. Barbano R, et al. Among authors: morritti m. Sci Rep. 2017 Mar 27;7:45283. doi: 10.1038/srep45283. Sci Rep. 2017. PMID: 28345661 Free PMC article.
Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients.
Parrella P, Barbano R, Pasculli B, Fontana A, Copetti M, Valori VM, Poeta ML, Perrone G, Righi D, Castelvetere M, Coco M, Balsamo T, Morritti M, Pellegrini F, Onetti-Muda A, Maiello E, Murgo R, Fazio VM. Parrella P, et al. Among authors: morritti m. Mol Cancer. 2014 Jun 4;13:142. doi: 10.1186/1476-4598-13-142. Mol Cancer. 2014. PMID: 24897960 Free PMC article.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Ciccarese M, et al. Among authors: morritti m. Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28. Breast Cancer Res Treat. 2017. PMID: 28353061
Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P. Pasculli B, et al. Among authors: morritti m. Front Oncol. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415. eCollection 2020. Front Oncol. 2020. PMID: 32903519 Free PMC article.
Combined analysis of miR-200 family and its significance for breast cancer.
Fontana A, Barbano R, Dama E, Pasculli B, Rendina M, Morritti MG, Melocchi V, Castelvetere M, Valori VM, Ravaioli S, Bravaccini S, Ciuffreda L, Graziano P, Maiello E, Copetti M, Fazio VM, Esteller M, Bianchi F, Parrella P. Fontana A, et al. Among authors: morritti mg. Sci Rep. 2021 Feb 3;11(1):2980. doi: 10.1038/s41598-021-82286-1. Sci Rep. 2021. PMID: 33536459 Free PMC article.
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S; Gruppo Oncologico dell’Italia Meridionale (GOIM). Orlando L, et al. Among authors: morritti mg. Breast. 2024 Apr 5;75:103725. doi: 10.1016/j.breast.2024.103725. Online ahead of print. Breast. 2024. PMID: 38615483 Free PMC article.
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S, Livraghi L, Gravina A, Martella F, D'Onofrio L, Morritti M, Michelotti A, Vici P, Mentuccia L, Porcu L, Orditura M, Puglisi F; ESEMPiO Group. Barni S, et al. Among authors: morritti m. J Geriatr Oncol. 2019 Nov;10(6):990-993. doi: 10.1016/j.jgo.2019.05.003. Epub 2019 May 13. J Geriatr Oncol. 2019. PMID: 31097340 No abstract available.
[High-dose chemotherapy of metastatic breast carcinoma].
Tartarone A, Aieta M, Morritti MG, Palomba G, Romano MP, Lelli G. Tartarone A, et al. Among authors: morritti mg. Clin Ter. 1998 May-Jun;149(3):227-30. Clin Ter. 1998. PMID: 9842107 Review. Italian.
16 results